~~<i id='F55015F01B'><strike id='F55015F01B'><tt id='F55015F01B'><pre id='F55015F01B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：Wikipedia 2025-09-30 18:59:10 - browse：11273

the shape of a medical note connected by dots and lines — health tech coverage from STAT — Adobe

In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： STAT Readout Newsletter: Today in biotech, life science news

leisure time

focus

leisure time

knowledge

explore

entertainment

AdobeThisarticleisadaptedfromthe2023editionofSTAT’sannualreport,“Rankingbiotech’stopventurecapitalfi

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

Medicare to cover more brain scans related to Alzheimer’s drugs

A public scorecard can help hold safety

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

knowledge

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

European regulators recommend Amylyx's ALS drug be rejected

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Doctors find melanoma drugs effective against rare brain cancer

How one medical school became remarkably diverse

Startup Neumora takes a novel depression drug to Phase 3

In age of alternative facts, a scholarly course on calling out crap

Sanders adds drug shortage policies to pandemic preparedness bill

At least 13 dead in Texas as scorching temps continue

Startup Neumora takes a novel depression drug to Phase 3

focus

Akero's treatment for NASH falls short in cirrhosis study

There’s no way to know how good AI health technologies are

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

In early work, researchers turn to CRISPR to treat Alzheimer's

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Readout LOUD podcast: Merger Mondays, Ozempic panic

leisure time

knowledge

explore

entertainment